雅培研发子宫内膜异位新药 数以百万女性将受益 发布时间：2012-9-18 来源：药品资讯网信息中心 美国耶鲁大学医学院生殖内分泌学和不孕部门HughTaylor在接受采访时表示，子宫内膜异位属于一种衰竭性疾病，每年全球都会有数以百万计的女性深受这种病症的干扰。日前雅培制药公司宣布，用于治疗子宫内膜异位病症的新药elagolix正式进入比较关键的三期临床试验阶段。 谈及该药物的临床试验时，雅培制药公司表示预计将于2016年正式向美国食品和药物监管局提交关于该药物的上市申请书。在正常情况下，子宫内膜覆盖于子宫体腔面，如因某种因素，使子宫内膜在身体其他部位生长，即可成为子宫内膜异位症。这种异位的内膜在组织学上不但有内膜的腺体，且有内膜间质围绕。在功能上随雌激素水平而有明显变化，即随月经周期而变化，但仅有部分受孕激素影响，能产生少量"月经"而引起种种临床现象。 子宫内膜异位有几种症状，最为常见的就是痛经以及慢性盆腔痛，这也是导致不孕症的罪魁祸首。世界子宫内膜异位症研究基金会的最新数据显示，每年全球约有一亿名女性患有子宫内膜异位病症，但是美国境内，子宫内膜异位患者的年度医药开支总额就高达200亿美元。
About Elagolix Elagolix inhibits gonadatropin releasing hormone (GnRH) receptors in the pituitary gland and ultimately reduces circulating sex hormone levels. To date, elagolix has been studied in over 20 clinical trials totaling more than 1,000 subjects. A Phase 2a trial of elagolix for the treatment of uterine fibroids is also ongoing.
About Endometriosis Endometriosis is associated with a multitude of symptoms, some of the most common of which include pain related both to menstruation (dysmenorrhea) as well as chronic pelvic pain throughout the menstrual cycle, and is a leading cause of infertility. The World Endometriosis Research Foundation estimates that there are approximately 100 million women worldwide who suffer from endometriosis. The annual direct and indirect costs of endometriosis are estimated to exceed $20 billion in the United States alone.
No comments:
Post a Comment